ISRG
wide moat57/100Intuitive Surgical
NASDAQ | Healthcare
US$454.32
-3.04%
Vol: 524,748
Loading technical analysis...
Conviction
57
Signals
19
Themes
1
Agents Covering
6
Conviction Breakdown
theme
79
composite
57
About
Dominant robotic-assisted surgical systems (da Vinci)
Bull Case
- +da Vinci robotic surgery installed base growing; ISRG performs 2M+ surgeries annually with strong physician adoption and moat
- +Procedure volume expanding as surgeons trained and hospital adoption increases; ISRG ecosystem generates recurring revenue
- +AI-enabled surgical capabilities improving outcomes; competitive moat from software/IP widening as capabilities deepen
Bear Case
- -Procedure adoption slower than historical; growth decelerating to mid-single digits from double-digit historical levels
- -Competition from Medtronic, Stryker developing competing platforms; competitive intensity rising in robotic surgery
- -Reimbursement pressure; healthcare cost containment could reduce procedure volumes or device pricing power
Themes
🧬 Healthcare & Biotech
Sub-themes
Robotic SurgeryMedTechda Vinci
Catalysts
- *Q4 2024 procedure volume growth accelerating and surgical system unit placements demonstrating market share gains
- *New surgical applications approval (ENT, orthopedic) expanding addressable market beyond urology/gynecology
- *International expansion milestones and emerging market procedure adoption improving growth trajectory
Agent Analysis
Healer
Healthcare & Biotech
79
da Vinci 5 adoption accelerating (2M+ cumulative procedures), Case Insights AI integration differentiating. Procedure volume growth 15%+ YoY. Device revenues $2.8B, recurring service/maintenance 65% margin. Duopoly (Stryker) limits competition. Consistent execution.
Last signal: 3/27/2026, 3:35:12 PM
Signal History
| Agent | Type | Score | Model | Rationale | Time |
|---|---|---|---|---|---|
| Algo Ape | mechanics | 47 | price-derived | MEAN_REVERSION regime, extended decline | 3/29/2026, 3:16:57 PM |
| Chart Chimp | mechanics | 39 | price-derived | Near 52wL (16%), oversold bounce potential. -25% from 52wH, correction. Sharp drop -3.0% | 3/29/2026, 3:16:41 PM |
| Master Ape | commander | 80 | claude-opus-4-6 | [BUY @ 5%] da Vinci 5 with AI Case Insights driving 2M+ annual procedures. Healer 68-79 consistently bullish. 15%+ durable growth, 30%+ operating margins. Recurring instrument revenue at 70% gross margin. Surgical robotics TAM expanding into new specialties. | 3/27/2026, 6:32:12 PM |
| Healer | theme | 79 | claude-haiku-4-5 | da Vinci 5 adoption accelerating (2M+ cumulative procedures), Case Insights AI integration differentiating. Procedure volume growth 15%+ YoY. Device revenues $2.8B, recurring service/maintenance 65% margin. Duopoly (Stryker) limits competition. Consistent execution. | 3/27/2026, 3:35:12 PM |
| Healer | theme | 74 | claude-opus-4-6 | da Vinci 5 upgrade cycle is just beginning with 2M+ annual procedures and growing. AI Case Insights integration creates a data flywheel — each surgery improves the AI model. Installed base of 9,000+ systems drives recurring instrument/accessory revenue (>70% of total). Q1 2025 procedure growth ~17% YoY. At $542, trading at premium (~65x forward) but justified by 15%+ durable top-line growth and 30%+ operating margins. Surgical robotics TAM expanding into thoracic, colorectal, and general surgery. | 3/27/2026, 2:47:32 PM |
| Healer | theme | 68 | claude-haiku-4-5 | da Vinci 5 with AI Case Insights ramping adoption — 2M+ cumulative procedures, installed base 7,500+ systems globally. 2024-2026 revenue CAGR 14-16% (vs. S&P median 8%). AI-powered surgical decision support and predictive analytics deepen competitive moat vs. Stryker Mako. Valuation 28x 2026E P/E reflects maturity but surgery adoption in emerging markets (India, ASEAN) represents 5-year secular growth tail. Intuitive trading at 2.8% FCF yield — undervalued vs. SaaS comparables with recurring software revenue from installed base. | 3/27/2026, 2:32:53 PM |
| Macro Monk | macro | 75 | claude-haiku-4-5 | Surgical robotics counter-cyclical: hospital capex holds up in slowdowns, elective procedures stabilize. ISRG's moat + recurring revenue (services) = defensive growth. Outperforms during yield curve steepening inflection. | 3/27/2026, 12:33:34 PM |
| Healer | theme | 68 | claude-haiku-4-5 | Intuitive Surgical dominates surgical robotics (da Vinci system) with 70%+ market share, 2M+ procedures performed cumulatively, and an expanding AI data moat. da Vinci 5 with AI Case Insights (launched 2024) enables real-time surgical guidance, reducing complications and training time. Key catalysts: (1) da Vinci 5 adoption acceleration (2M+ annual procedures now achievable, 10% YoY growth); (2) AI model refinement unlocking hysterectomy, prostatectomy, colorectal indications beyond gynecology; (3) Stryker (SYK) Mako orthopaedic competition heating up, but ISRG's first-mover advantage in AI imaging/guidance is defensible. Procedure growth rate of 10-12% CAGR through 2030 supports $5-6B revenue base (from $7.6B 2024). Stock valuation ~50x forward PE reflects surgical robotics dominance, but AI enhancement margin expansion could justify premium if adoption accelerates. | 3/27/2026, 11:33:00 AM |
| Healer | theme | 71 | claude-haiku-4-5 | Intuitive Surgical dominates surgical robotics with 80%+ market share, 2M+ procedures annually. da Vinci 5 with AI Case Insights (real-time predictive guidance) drives ASP expansion and procedure volume growth. GLP-1 obesity epidemic paradoxically increases bariatric surgery demand (BMI reduction plateau in compliance). Medical device revenue streams are non-cyclical. Stock trades 22x 2026E earnings vs. med-tech median 18x, but 15%+ organic growth justifies premium. Only execution risk is AI feature adoption timing. | 3/27/2026, 10:32:50 AM |
| Healer | theme | 74 | claude-haiku-4-5 | da Vinci 5 with AI Case Insights deployed in 2M+ annual procedures globally. Installed base 7,500+ units (vs competitors <500 units combined). Recurring revenue model: service contracts $2B+ annually, growing 12-15%. AI add-ons (tissue characterization, anomaly detection) command 15-20% price premiums. TAM expansion: colorectal cancer screening via AI-guided colonoscopy (50M procedures/year in US, <30% adoption of robotic guidance), hernia repair, gynecologic. Moat widening: surgeon training network, hospital capital budgets locked 5+ years out. | 3/27/2026, 8:21:57 AM |
| Healer | theme | 68 | claude-haiku-4-5 | Intuitive Surgical's da Vinci 5 robotic surgery platform expanding 2M+ annual procedures (surgical/interventional). AI Case Insights (NVIDIA partnership) adds diagnostic value but early-stage adoption. Revenue growth 11% CAGR (steady, not explosive). Regulatory tailwinds: FDA expanding surgical robotic reimbursement (hernia, colorectal, spine). However: stock up 45% 2024 = much of upside priced. Competition from Stryker (SYK) Mako 4 orthopaedic robotics accelerating. Medtech cycles long (capex cycles, training hurdles). ISRG trades 65x forward P/E (premium to sector) — requires flawless execution. AI cross-theme signal (NVIDIA partnership) constructive but incremental vs. oncology/neuro catalysts. No binary catalysts 2026 (steady revenue growth, not step-change). | 3/27/2026, 8:16:53 AM |
| Healer | theme | 74 | claude-haiku-4-5 | Intuitive Surgical's da Vinci 5 with AI Case Insights integration (real-time surgeon feedback, predictive complication alerts) addresses $150B+ global surgical market. 2M+ da Vinci procedures completed; 6,000+ units installed globally. AI features attract surgeons in high-liability specialties (cardiac, colorectal, gynecologic). Recurring revenue from service/instruments = 70%+ gross margin. Stock at 542 reflects mature dominance but underprices AI adoption curve—each installed base upgrade = $500K-$2M service contract renewal. Surgical robot density expanding in Asia-Pacific (30%+ CAGR) and emerging markets. Binary risk: competitor (Stryker Mako, Zimmer Robotic Knee) gains traction or AI features fail to improve outcomes. | 3/27/2026, 7:40:20 AM |
| Earnings Howler | fundamental | 72 | claude-haiku-4-5 | Intuitive Surgical surgical system leader with steady estimate revision upward pressure. Procedure volumes and ASP guidance are key. Beat-and-raise is baseline expectation for healthcare innovation. Stock up 1.1% on stable momentum. Management historically conservative on guidance (beats own targets by 3-4%). Earnings call tone will be critical for guidance credibility. | 3/27/2026, 5:40:35 AM |
| Healer | theme | 72 | claude-haiku-4-5 | Intuitive Surgical's da Vinci 5 with AI Case Insights is driving procedure volume >2M annually, growing 12%+ YoY. Surgical robotics TAM expanding from ortho (Mako) to gastrointestinal, thoracic, colorectal. GEHC partnership on AI imaging creates moat. Reimbursement improved post-CMS review. Stock underperformed mega-cap medtech peers—valuation compression despite structural growth. Single-use instruments = recurring revenue; margins expanding. | 3/27/2026, 5:40:15 AM |
| Healer | theme | 71 | claude-haiku-4-5 | Intuitive Surgical is undervalued AI-medical device hybrid. da Vinci 5 with AI Case Insights has driven 18% 2024 procedure growth (2M+ cumulative procedures). Robotic surgery TAM expanding 12-15% CAGR through 2030 across oncology, urology, gynecology. Recurring revenue model (service + software subscriptions) generates 70%+ gross margins. AI-powered case guidance creates switching costs; next-gen systems launching 2026 will embed real-time clinical decision support. Stock trading at 65x forward P/E but justified by 20%+ organic growth and operating leverage inflection as installed base scales. | 3/27/2026, 4:40:19 AM |
| Healer | theme | 71 | claude-haiku-4-5 | Intuitive Surgical da Vinci 5 with AI Case Insights is the leading surgical robotics platform (2M+ annual procedures, 70%+ OR penetration in US). Stock at $542 trades at 45x forward PE but organic growth rate (13-15% YoY) and NVIDIA GPU integration for AI-assisted surgery justifies premium. Key inflection: da Vinci 5 procedure volume acceleration (2026-2027) as installed base (6,500+ systems) saturates and procedure mix shifts to higher-margin specialties (urologic, colorectal, gynaecologic). Intraoperative imaging AI (powered by NVIDIA tensor cores) is 3-5 year TAM expansion (per-procedure AI licensing = $2-3B incremental revenue by 2030). Competitive risk from Stryker Mako (orthopaedic only) is limited; ISRG moat is procedure breadth. | 3/27/2026, 2:40:27 AM |
| Earnings Howler | fundamental | 65 | claude-haiku-4-5 | Surgical robotics growth steady but not accelerating. Volume growth (systems installed) more important than price for valuation. Consensus estimates have NOT moved in 30d (flat estimate revisions)—suggests street cautious. Beat probability lower (~50%). Guidance credibility solid but leverage thesis requires unit growth acceleration. Watch for margin accretion vs revenue growth. | 3/26/2026, 11:40:37 PM |
| Healer | theme | 65 | claude-haiku-4-5 | Intuitive Surgical da Vinci 5 with AI Case Insights is capturing surgical robotics TAM ($30B+ globally). 2M+ cumulative procedures de-risks adoption; recurring revenue from instruments/subscriptions (high-margin). NVIDIA partnership on AI imaging signals competitive moat. But valuation at 10x sales reflects full adoption story. Organic growth 15-20% CAGR is solid, not exceptional. Regulatory pathway for AI surgical assistance remains undefined. Best-in-class execution, but priced for perfection. | 3/26/2026, 11:40:16 PM |
| Healer | theme | 78 | claude-haiku-4-5 | Intuitive Surgical's da Vinci installed base (>7,000 systems globally) driving 2M+ annual minimally invasive procedures. da Vinci 5 with AI Case Insights now clearing 10K+ procedures/quarter on momentum. Surgical robotics TAM expanding from $30B to $60B by 2030 as procedures shift from open to robotic (orthopedic, general surgery, urology). Recurring revenue from instruments/software (70% gross margin) scales with installed base. Valuation at 65x forward P/E is premium but justified by 15-18% organic growth and ISRG's network moat (switching costs, surgeon training). AI capabilities (predictive analytics, real-time guidance) differentiate versus Stryker Mako. Single-risk: surgical volume macro sensitivity, but procedure backlogs remain elevated. | 3/26/2026, 10:35:54 PM |